Transplanted patient outcomes depend on several factors, including patient selection [1,3,5]; tumor biology (i.e., alpha-fetoprotein level) [3,5]; tumor-related features such as size, presence of liver metastasis or multinodularity, vascular invasion, and poor tumor differentiation [4,5,6,7]; tumor metabolic activity on FDG-PET imaging; and response to locoregional bridging therapy [3,4,5,8,9,10,11]. The gene discussed is AFP; the disease is neoplasm.